These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38402640)

  • 21. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
    Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
    Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Wang Z; Liu H; Zhang W
    J Immunother; 2025 Jan; 48(1):18-26. PubMed ID: 38800996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
    Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
    Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
    Wu W; Chen L; Jia G; Tang Q; Han B; Xia S; Jiang Q; Liu H
    Cancer Med; 2023 Jul; 12(14):15676-15690. PubMed ID: 37283287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
    Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
    JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
    Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
    J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamic alteration and prognostic significance of tumor-associated CD68
    Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG
    Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 35. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling.
    Zhou X; Qiu S; Nie L; Jin D; Jin K; Zheng X; Yang L; Wei Q
    Front Oncol; 2020; 10():1429. PubMed ID: 32974156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor clinical outcomes and immunoevasive contexture in SIRPα
    Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
    Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks.
    Xu Y; Sun X; Liu G; Li H; Yu M; Zhu Y
    Front Immunol; 2023; 14():1301157. PubMed ID: 38299148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
    Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
    EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.